(Q46753935)

English

Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18274979

Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18274979

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

George J Kontoghiorghes

5

object named as

George J Kontoghiorghes

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18274979

author name string

Annita Kolnagou

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18274979

Yiannis Michaelides

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18274979

Christos Kontos

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18274979

Kyriacos Kyriacou

4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18274979

publication date

1 January 2008

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18274979

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18274979

32

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18274979

1-2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18274979

17-28

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18274979

Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726491

21 January 2018

Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726491

21 January 2018

Ultrastructural pathology of the heart in patients with beta-thalassaemia major.

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726491

21 January 2018

Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726491

21 January 2018

Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726491

21 January 2018

Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726491

21 January 2018

Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726491

21 January 2018

Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726491

21 January 2018

Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726491

21 January 2018

The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726491

21 January 2018

Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726491

21 January 2018

Iron-chelating therapy with the new oral agent ICL670 (Exjade).

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726491

21 January 2018

Effects of ICL670 (deferasirox) on cardiac iron concentrations

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726491

21 January 2018

In Vitro Screening of Iron Chelators Using Models of Free Radical Damage

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726491

21 January 2018

Identifiers

10.1080/03630260701726491

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18274979

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18274979

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46753935&oldid=2129880305"